In AML, in which an average of 2.76 genetic abnormalities are detected per patient at initial diagnosis [140], satisfactory results have not been obtained with single-targeted therapy, such as ABL1 inhibitors in CML. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.